UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pre-existing anti–polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer

Journal of allergy and clinical immunology, 2016-05, Vol.137 (5), p.1610-1613.e7

2016

Volltextzugriff (PDF)

Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer

Journal of allergy and clinical immunology, 2016-12, Vol.138 (6), p.1712-1715

2016

Volltextzugriff (PDF)

Femoral Vascular Closure Devices and Bleeding, Hemostasis, and Ambulation Following Percutaneous Coronary Intervention

Journal of the American Heart Association, 2023-01, Vol.12 (1), p.e025666-e025666

2023

Volltextzugriff (PDF)

Interplay between PCI access site, anticoagulant agent, and bleeding: Insights from the REGULATE-PCI randomized trial

The American heart journal, 2020-05, Vol.223, p.84-86

2020

Volltextzugriff (PDF)

SUBCUTANEOUS FIXA INHIBITOR PROVIDES PROLONGED ANTICOAGULATION: THE FIRST SUCCESSFUL SUBCUTANEOUS APPLICATION OF AN APTAMER

Journal of the American College of Cardiology, 2010-03, Vol.55 (10), p.A172.E1618-A172.E1618

2010

Volltextzugriff (PDF)

Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism

Arteriosclerosis, thrombosis, and vascular biology, 2010-03, Vol.30 (3), p.382-387

2010

Volltextzugriff (PDF)

Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes

European heart journal. Acute cardiovascular care, 2019-09, Vol.8 (6), p.520-526

2019

Volltextzugriff (PDF)

A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR Phase IIb trial

The American heart journal, 2011-02, Vol.161 (2), p.261-268.e2

2011

Volltextzugriff (PDF)

Navigating the Future of Cardiovascular Drug Development—Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference

Cardiovascular drugs and therapy, 2017-08, Vol.31 (4), p.445-458

2017

Volltextzugriff (PDF)

FEMORAL VASCULAR CLOSURE DEVICES AND BLEEDING, HEMOSTASIS, AND AMBULATION FOLLOWING PERCUTANEOUS CORONARY INTERVENTION

Journal of the American College of Cardiology, 2022-03, Vol.79 (9), p.831

2022

Volltextzugriff (PDF)

Feasibility of at-home motor assessments using wireless technology in patients with myelopathy: year 1 follow up of CYGNET, an observational study of patients with adrenomyeloneuropathy (P6-6.006)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

Translating Nucleic Acid Aptamers to Antithrombotic Drugs in Cardiovascular Medicine

Journal of cardiovascular translational research, 2010-12, Vol.3 (6), p.704-716

2010

Volltextzugriff (PDF)

Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-07, Vol.24 (4), p.e167-e172

2018

Volltextzugriff (PDF)

The 1st WFH Gene Therapy Round Table: Understanding the landscape and challenges of gene therapy for haemophilia around the world

Haemophilia : the official journal of the World Federation of Hemophilia, 2019-03, Vol.25 (2), p.189-194

2019

Volltextzugriff (PDF)

Inhibition of factor IXa by the pegnivacogin system during cardiopulmonary bypass: a potential substitute for heparin. A study in baboons

European journal of cardio-thoracic surgery, 2016-02, Vol.49 (2), p.682-689

2016

Volltextzugriff (PDF)

Sustained Inhibition of Factor IXa by Subcutaneous RB006 With Active Reversal: First-in-Human Experience With the REG2 System

Chest, 2010-10, Vol.138 (4), p.851A-851A

2010

Volltextzugriff (PDF)

Response to Letter Regarding Article, “Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both”

Circulation (New York, N.Y.), 2011-05, Vol.123 (18)

2011

Volltextzugriff (PDF)

FACTOR IXA INHIBITION WITH REG1 PROVIDES RAPID ONSET, STABLE AND ACTIVELY CONTROLLED ANTICOAGULATION DURING PCI

Journal of the American College of Cardiology, 2010-03, Vol.55 (10), p.A206.E1940-A206.E1940

2010

Volltextzugriff (PDF)

Effects of valsartan hct versus amlodipine on 24 hour blood pressure control in hypertensive african americans: the aadvance trial

American journal of hypertension, 2004-05, Vol.17 (5), p.S124-S124

2004

Volltextzugriff (PDF)

P-252: Effects of valsartan hct versus amlodipine on 24 hour blood pressure control in hypertensive african americans: the aadvance trial

American journal of hypertension, 2004-05, Vol.17 (S1), p.124A-124A

2004

Volltextzugriff (PDF)

Valsartan improves early morning adn 24-hour heart rate variability

Journal of the American College of Cardiology, 2003-03, Vol.41 (6), p.109-109

2003

Volltextzugriff (PDF)

Response to The J-Point Revisited

Hypertension (Dallas, Tex. 1979), 2008-05, Vol.51 (5), p.e35-e35

2008

Volltextzugriff (PDF)

Effect of Antecedent Hypertension and Follow-Up Blood Pressure on Outcomes After High-Risk Myocardial Infarction. Commentary

Hypertension (Dallas, Tex. 1979), 2008, Vol.51 (1)

2008

Volltextzugriff (PDF)

P-218: Comparison of the effects of valsartan HCT versus amlodipine on 24-hour abpm blood pressure in african americans with mild to moderate hypertension: The aadvance trial

American journal of hypertension, 2004-05, Vol.17 (S1), p.112A-113A

2004

Volltextzugriff (PDF)

Comparison of the effects of valsartan HCT versus amlodipine on 24-hour abpm blood pressure in african americans with mild to moderate hypertension: the aadvance trial

American journal of hypertension, 2004-05, Vol.17 (5), p.S112-S113

2004

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Aktive Filter

ThemaMiddle Aged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)
Japanisch
(2)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Pre-existing anti–polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer

Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer

Femoral Vascular Closure Devices and Bleeding, Hemostasis, and Ambulation Following Percutaneous Coronary Intervention

Interplay between PCI access site, anticoagulant agent, and bleeding: Insights from the REGULATE-PCI randomized trial

SUBCUTANEOUS FIXA INHIBITOR PROVIDES PROLONGED ANTICOAGULATION: THE FIRST SUCCESSFUL SUBCUTANEOUS APPLICATION OF AN APTAMER

Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism

Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes

A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR Phase IIb trial

Navigating the Future of Cardiovascular Drug Development—Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference

FEMORAL VASCULAR CLOSURE DEVICES AND BLEEDING, HEMOSTASIS, AND AMBULATION FOLLOWING PERCUTANEOUS CORONARY INTERVENTION

Feasibility of at-home motor assessments using wireless technology in patients with myelopathy: year 1 follow up of CYGNET, an observational study of patients with adrenomyeloneuropathy (P6-6.006)

Translating Nucleic Acid Aptamers to Antithrombotic Drugs in Cardiovascular Medicine

Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project

The 1st WFH Gene Therapy Round Table: Understanding the landscape and challenges of gene therapy for haemophilia around the world

Inhibition of factor IXa by the pegnivacogin system during cardiopulmonary bypass: a potential substitute for heparin. A study in baboons

Sustained Inhibition of Factor IXa by Subcutaneous RB006 With Active Reversal: First-in-Human Experience With the REG2 System

Response to Letter Regarding Article, “Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both”

FACTOR IXA INHIBITION WITH REG1 PROVIDES RAPID ONSET, STABLE AND ACTIVELY CONTROLLED ANTICOAGULATION DURING PCI

Effects of valsartan hct versus amlodipine on 24 hour blood pressure control in hypertensive african americans: the aadvance trial

P-252: Effects of valsartan hct versus amlodipine on 24 hour blood pressure control in hypertensive african americans: the aadvance trial

Valsartan improves early morning adn 24-hour heart rate variability

Response to The J-Point Revisited

Effect of Antecedent Hypertension and Follow-Up Blood Pressure on Outcomes After High-Risk Myocardial Infarction. Commentary

P-218: Comparison of the effects of valsartan HCT versus amlodipine on 24-hour abpm blood pressure in african americans with mild to moderate hypertension: The aadvance trial

Comparison of the effects of valsartan HCT versus amlodipine on 24-hour abpm blood pressure in african americans with mild to moderate hypertension: the aadvance trial

Aktive Filter

Suchergebnisse filtern